glp 1 and autoimmune hepatitis A Case of Severe Cholestatic Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 Glucose-dependent Insulinotropic Polypeptide Receptors Using GLP-1 Agonists with Biologics

Likewise, multiple large clinical studies with various GLP-1 RAs have shown a more favorable trend in lipid profiles with GLP-1 RAs, although these were not evaluated as the primary outcomes (Table 2)

Several of these drugs (exenatide (Byetta and Bydureon), liraglutide (Victoza for diabetes, Saxenda for obesity) albiglutide (Tanzeum), dulaglutide (Trulicity), and lixisenatide (Lyxumia in Europe, Adlyxin in the United States) have been around for at least ten years

V., Hertz, C

No patients receiving GLP-1 RAs were excluded due to loss of follow-up, while 8 patients (0.2%) who did not receive GLP-1 RAs were excluded for this reason (Supplemental Table 3)